Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plozasiran in Severe Hypertriglyceridemia at High Risk of Acute Pancreatitis
NCT06880770Phase 3Recruiting
- Sponsor
- Arrowhead Pharmaceuticals
- Start
- Apr 2025
- Primary completion
- Mar 2029
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 27
01
Overview
Phase 3, randomised, double-blind trial in hypertriglyceridemia comparing Plozasiran Injection with Placebo (2 arms). Primary endpoint: Time to First Occurrence of Positively Adjudicated Acute Pancreatitis Event up to 50 months. Started Apr 2025; status: recruiting.
02
Drugs
plozasiran
03
Conditions
hypertriglyceridemia
Beyond the preview
Go deeper on NCT06880770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06880770.